By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics developer Diagnoplex today said it has closed a Series A financing extension with Debiopharm Group.

Diagnoplex said today that Debiopharm has committed to invest “a substantial amount” in the company, depending on certain milestones, and has provided half of that commitment up front, although the company did not provide specific financial details about the investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.